Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Large Infarct CorePost-stroke Lymphocytopenia
Interventions
DRUG

Methylprednisolone sodium succinate

Methylprednisolone sodium succinate Intravenous injection of methylprednisolone sodium succinate (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ vial) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.

DRUG

Normal Saline

Intravenous injection of placebo (normal saline) (Chongqing Lummy Pharmaceutical Co., Ltd., 40mg/ bottle) with a dose of 2mg/kg (maximum dose of 160mg), once daily, for three consecutive days. The initial study drug will be administered as soon as possible after randomization. It is recommended that the initial study drug administrated before arterial access closure, but it should not be delayed more than 2 hours after arterial access closure.

Trial Locations (1)

350005

RECRUITING

Department of Neurology, the First Affiliated Hospital Fujian Medical University, Fuzhou

All Listed Sponsors
lead

YiLin

OTHER

NCT07202143 - Methylprednisolone for Stroke With Large Infarct Core and Post-stroke Lymphocytopenia | Biotech Hunter | Biotech Hunter